Skip to main content

ORIGINAL RESEARCH article

Front. Endocrinol.
Sec. Clinical Diabetes
Volume 15 - 2024 | doi: 10.3389/fendo.2024.1440286

Effect of probiotics on glycemic control and lipid profiles in patients with type 2 diabetes mellitus: A randomized, doubleblind, controlled trial

Provisionally accepted
Xuchao Peng Xuchao Peng Hong Xian Hong Xian Ning Ge Ning Ge Lisha Hou Lisha Hou Tianjiao Tang Tianjiao Tang Donmgmei Xie Donmgmei Xie Langli Gao Langli Gao Jirong Yue Jirong Yue *
  • West China Hospital, Sichuan University, Chengdu, China

The final, formatted version of the article will be published soon.

    This double-blind, placebo-controlled, randomized (1:1) clinical trial was conducted at the West China Hospital, Sichuan University, from March to September 2017. Eligible participants included adults aged 18 years and older, living in the community, diagnosed with type 2 Diabetes Mellitus according to ADA guidelines, capable of self-managing their diabetes, and able to visit the study site for follow-up. The intervention group received 25 ml of a probiotic beverage containing with over 10^8 CFU/mL of Lactobacillus, administered four times daily. An equal volume of inactivated Lactobacillus was administered to the control group and the control group was administered the same volume of inactivated Lactobacillus. This study aimed to evaluate the effectiveness of probiotics on glycemic control and other diabetes-related outcomes in patients with type 2 diabetes patients. The primary outcomes were changes in HbA1c and FBG levels post-intervention. Investigators, participants, and study site personnel were blinded to the treatment allocation until the conclusion of the study. Of the 490 participants screened, 213 were randomized to either the probiotics group (n = 103) or the placebo group (n = 110). After 16 weeks of follow-up, the probiotic group showed reductions in HbA1c [-0.18 (-0.70 to 0.18)] and FBG [-0.78 (-1.78 to 0.07)] post-intervention, similar to the placebo group with reductions in HbA1c [-0.20 (-0.63 to 0.10)] and FBG [-0.63 (-1.59 to 0.42)], but these changes were not statistically significant in PP and ITT analyses (P>0.05). Adverse events were similarly distributed among groups, indicating comparable safety profiles. This double-blind, randomized, placebo-controlled clinical trial was registered in the Chinese Clinical Trial Registry (ChiCTR-POR-17010850). Overall, 16-week probiotic supplementation showed no beneficial effects on glycemic control, lipid profiles, or weight.

    Keywords: Probiotics, lipid profile, type 2 diabetes mellitus, randomized controlled trial, Glycemic

    Received: 29 May 2024; Accepted: 26 Aug 2024.

    Copyright: © 2024 Peng, Xian, Ge, Hou, Tang, Xie, Gao and Yue. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) or licensor are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.

    * Correspondence: Jirong Yue, West China Hospital, Sichuan University, Chengdu, China

    Disclaimer: All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.